William Blair Upgrades Genmab A/S (NASDAQ:GMAB) to Outperform

Genmab A/S (NASDAQ:GMAB - Get Free Report) was upgraded by stock analysts at William Blair from a "market perform" rating to an "outperform" rating in a research note issued to investors on Tuesday, MarketBeat reports.

GMAB has been the subject of a number of other reports. HC Wainwright reiterated a "buy" rating and issued a $50.00 price objective on shares of Genmab A/S in a research note on Thursday, January 23rd. BNP Paribas raised Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. Leerink Partnrs raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. Sanford C. Bernstein upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Friday, December 20th. Finally, Leerink Partners upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target for the company in a research report on Thursday, February 13th. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Genmab A/S has a consensus rating of "Moderate Buy" and an average target price of $42.17.

Genmab A/S Stock Performance

Shares of NASDAQ:GMAB opened at $21.98 on Tuesday. The company has a market capitalization of $14.55 billion, a P/E ratio of 12.63, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98. The company's 50-day moving average is $21.30 and its 200 day moving average is $22.59. Genmab A/S has a fifty-two week low of $18.64 and a fifty-two week high of $31.88.

Remove Ads

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. As a group, research analysts predict that Genmab A/S will post 1.45 earnings per share for the current year.

Hedge Funds Weigh In On Genmab A/S

A number of hedge funds have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. boosted its stake in Genmab A/S by 94.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company's stock worth $636,000 after purchasing an additional 12,654 shares during the period. AIMZ Investment Advisors LLC bought a new position in Genmab A/S during the fourth quarter valued at $3,525,000. HighTower Advisors LLC bought a new position in shares of Genmab A/S during the third quarter valued at approximately $273,000. Verition Fund Management LLC bought a new position in shares of Genmab A/S in the third quarter worth about $709,000. Finally, FMR LLC grew its stake in Genmab A/S by 13.5% in the 3rd quarter. FMR LLC now owns 278,194 shares of the company's stock worth $6,782,000 after acquiring an additional 33,076 shares in the last quarter. Institutional investors own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.